Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine-Reference-Cited by-同舟云学术

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine

Published:2015-12 Issue:1 Volume:12 Page:
ISSN:1743-422X
Container-title:Virology Journal
language:en
Short-container-title:Virol J

Author:

Cox Freek,Saeland Eirikur,Baart Matthijs,Koldijk Martin,Tolboom Jeroen,Dekking Liesbeth,Koudstaal Wouter,Lövgren Bengtsson Karin,Goudsmit Jaap,Radošević Katarina

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Virology

Link

http://link.springer.com/content/pdf/10.1186/s12985-015-0435-9

Reference53 articles.

1. WHO. Influenza. Fact sheet 211. 2009 http://www.whoint/mediacentre/factsheets/fs211/en/ .

2. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189–202. PubMed PMID: 23327522.

3. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175(1):59–68. PubMed PMID: 2309452.

4. Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA. Influenza B virus in seals. Science. 2000;288(5468):1051–3. PubMed PMID: 10807575.

5. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56(1):152–79. PubMed Pubmed Central PMCID: 372859.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus;Frontiers in Immunology;2022-09-30

2. Development and laboratory production of virus-like immune-stimulating complexes based on saponins and evaluation of their adjuvant potential using mice immunisation with influenza antigens;Biological Products. Prevention, Diagnosis, Treatment;2022-06-03

3. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity;Vaccines;2021-01-21

4. Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers;2019-10-18

5. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™;Vaccine;2017-10